81 related articles for article (PubMed ID: 16770788)
1. Thapsigargin resistance in human prostate cancer cells.
O'Neill JP; Velalar CN; Lee DI; Zhang B; Nakanishi T; Tang Y; Selaru F; Ross D; Meltzer SJ; Hussain A
Cancer; 2006 Aug; 107(3):649-59. PubMed ID: 16770788
[TBL] [Abstract][Full Text] [Related]
2. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
[TBL] [Abstract][Full Text] [Related]
3. Effects of various amino acid 256 mutations on sarcoplasmic/endoplasmic reticulum Ca2+ ATPase function and their role in the cellular adaptive response to thapsigargin.
Yu M; Lin J; Khadeer M; Yeh Y; Inesi G; Hussain A
Arch Biochem Biophys; 1999 Feb; 362(2):225-32. PubMed ID: 9989931
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells.
Lee DI; Sumbilla C; Lee M; Natesavelalar C; Klein MG; Ross DD; Inesi G; Hussain A
Arch Biochem Biophys; 2007 Aug; 464(1):19-27. PubMed ID: 17475205
[TBL] [Abstract][Full Text] [Related]
5. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of P-glycoprotein in L1210/VCR cells is associated with changes in several endoplasmic reticulum proteins that may be partially responsible for the lack of thapsigargin sensitivity.
Seres M; Poláková E; Krizanová O; Hudecová S; Klymenko SV; Breier A; Sulová Z
Gen Physiol Biophys; 2008 Sep; 27(3):211-21. PubMed ID: 18981537
[TBL] [Abstract][Full Text] [Related]
7. [Expression of PIAS3 an inhibitor of activated STAT3 protein in human prostate cancer].
Gan L; Yin ZF; Li M
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):419-21. PubMed ID: 18581899
[TBL] [Abstract][Full Text] [Related]
8. Gene amplification and transcriptional upregulation of the sarco/endoplasmic reticulum Ca2+ transport ATPase in thapsigargin-resistant hamster smooth muscle cells.
Rishi AK; Yu M; Tsai-Wu JJ; Belani CP; Fontana JA; Baker DL; Periasamy M; Hussain A
Nucleic Acids Res; 1998 Oct; 26(19):4529-37. PubMed ID: 9742259
[TBL] [Abstract][Full Text] [Related]
9. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profile of prostate cancer cell lines: effect of nerve growth factor treatment.
Sigala S; Bodei S; Missale C; Zani D; Simeone C; Cunico SC; Spano PF
Mol Cell Endocrinol; 2008 Mar; 284(1-2):11-20. PubMed ID: 18280641
[TBL] [Abstract][Full Text] [Related]
11. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin receptors in hormone-independent prostate cancer cell line DU145: presence of two variants of angiotensin type 1 receptor.
Sidorkiewicz M; Rebas E; Szymajda M; Ławnicka H; Pawlikowski M; Lachowicz A
Med Sci Monit; 2009 Apr; 15(4):BR106-10. PubMed ID: 19333191
[TBL] [Abstract][Full Text] [Related]
14. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells.
Kojima K; Ohhashi R; Fujita Y; Hamada N; Akao Y; Nozawa Y; Deguchi T; Ito M
Biochem Biophys Res Commun; 2008 Aug; 373(3):423-8. PubMed ID: 18573234
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
16. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
Yen WC; Lamph WW
Prostate; 2006 Feb; 66(3):305-16. PubMed ID: 16245282
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells.
Horiguchi A; Zheng R; Shen R; Nanus DM
Prostate; 2008 Jun; 68(9):975-84. PubMed ID: 18361411
[TBL] [Abstract][Full Text] [Related]
19. CCR2 expression correlates with prostate cancer progression.
Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
[TBL] [Abstract][Full Text] [Related]
20. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
